Brought to you by 
Mitsubishi Tanabe Pharma partners MT210 with Cyrenaic Pharmaceuticals
02 Jul 2014
Executive Summary
Mitsubishi Tanabe Pharma Corp. licensed Cyrenaic Pharmaceuticals Inc. exclusive rights outside of Asia (including China, Japan, India, and South Korea) to its Phase I 5-HT2A/Sigma-2 antagonist MT210 for schizophrenia.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com